Cyberlux wins US patents for multiple lighting technology applications: related news

Cyberlux wins US patents for multiple lighting technology applications

May 7, 2008—Cyberlux Corporation, a leading provider of LED lighting solutions, announced that the US Patent Office has recently awarded patent protection for 29 claims contained within two of the company's patent filings related to multi-mode solid-state lighting. These 29 claims provide the company with patent protection for its WatchDog and BrightEye family of tactical lighting products, as well as future product releases, says the company.

Cyberlux Corporation Awarded U.S. Patent Claims for Multiple Lighting Technology Applications

RESEARCH TRIANGLE, N.C., May 2 /PRNewswire-FirstCall/ -- Cyberlux Corporation (OTC Bulletin Board: CYBL - News), a leading provider of LED lighting solutions, announced today that the U.S. Patent Office has recently awarded patent protection for 29 claims contained within two of the Company's patent filings that address the apparatus and methods for providing multi-mode solid-state lighting. These 29 claims provide the Company with patent protection that extends to its WatchDog and BrightEye family of tactical lighting products, as well as other future product releases.

Cyberlux Receives Patent Protection For Claims Of Multiple Lighting Technology Applications - Quick Facts [CYBL.OB]

5/2/2008 2:26:23 PM Cyberlux Corp. (CYBL.OB) on Friday said that the US patent office has recently awarded patent protection for 29 claims contained within two of the company's patent filings that address the apparatus and methods for providing multi-mode solid-state lighting.

Cyberlux Corporation Awarded U.S. Patent Claims for Multiple Lighting Technology Applications

(BULLETIN BOARD: CYBL) , a leading provider of LED lighting solutions, announced today that the U.S. Patent Office has recently awarded patent protection for 29 claims contained within two of the Company's patent filings that address the apparatus and methods for providing multi-mode solid-state lighting. These 29 claims provide the Company with patent protection that extends to its WatchDog and BrightEye family of tactical lighting products, as well as other future product releases.

Mylan wins generic Prilosec patent litigation

Add our medical news to digg - Mylan wins generic Prilosec patent litigation Add our medical news to NewsVine - Mylan wins generic Prilosec patent litigation Add our medical news to Fark - Mylan wins generic Prilosec patent litigation Add our medical news to Furl - Mylan wins generic Prilosec patent litigation Add our medical news to Shadows - Mylan wins generic Prilosec patent litigation Add our medical news to YahooMyWeb - Mylan wins generic Prilosec patent litigation Add our medical news to Reddit -Mylan wins generic Prilosec patent litigation Add our medical news to StumbleUpon - Mylan wins generic Prilosec patent litigation Add our medical news to Facebook - Mylan wins generic Prilosec patent litigation

Telik announces patents on TELINTRA compounds

Add our medical news to digg - Telik announces patents on TELINTRA compounds Add our medical news to NewsVine - Telik announces patents on TELINTRA compounds Add our medical news to Fark - Telik announces patents on TELINTRA compounds Add our medical news to Furl - Telik announces patents on TELINTRA compounds Add our medical news to Shadows - Telik announces patents on TELINTRA compounds Add our medical news to YahooMyWeb - Telik announces patents on TELINTRA compounds Add our medical news to Reddit -Telik announces patents on TELINTRA compounds Add our medical news to StumbleUpon - Telik announces patents on TELINTRA compounds Add our medical news to Facebook - Telik announces patents on TELINTRA compounds

Biopure Corporation wins European patent challenge

Add our medical news to digg - Biopure Corporation wins European patent challenge Add our medical news to NewsVine - Biopure Corporation wins European patent challenge Add our medical news to Fark - Biopure Corporation wins European patent challenge Add our medical news to Furl - Biopure Corporation wins European patent challenge Add our medical news to Shadows - Biopure Corporation wins European patent challenge Add our medical news to YahooMyWeb - Biopure Corporation wins European patent challenge Add our medical news to Reddit -Biopure Corporation wins European patent challenge Add our medical news to StumbleUpon - Biopure Corporation wins European patent challenge Add our medical news to Facebook - Biopure Corporation wins European patent challenge

UniPixel acquires Display Technology patents

Uni-Pixel, the developer of color display technology called Time Multiplexed Optical Shutter ("TMOS"), has reached an agreement to acquire a block of patents that are applicable to UniPixel’s TMOS display technology. The acquisition of the patents increases the total number of UniPixel’s TMOS display-related patents to one hundred and six (106) patents issued and filed. The patent transaction is a direct result of collaboration efforts entered into during 2007 surrounding the development and assembly of its TMOS display technology.

UniPixel Acquires Display Technology Patents

THE WOODLANDS, Texas, May 6 /PRNewswire-FirstCall/ -- Uni-Pixel, Inc. (OTC Bulletin Board: UNXL), the developer of color display technology called Time Multiplexed Optical Shutter ("TMOS"), today announced it has reached an agreement to acquire a block of patents that are applicable to UniPixel's TMOS display technology. The acquisition of the patents increases the total number of UniPixel's TMOS display-related patents to one hundred and six (106) patents issued and filed. The patent transaction is a direct result of collaboration efforts entered into during 2007 surrounding the development and assembly of its TMOS display technology.

Cyberlux Corporation Awarded U.S. Patent Claims for Multiple Lighting Technology Applications

Cyberlux Corporation Invited to Participate in National Guard Disaster Response Exercise with BrightEye Tactical LED Lighting Systems

Antigua Doesn't See Settlement With US Over WTO Plan To Let It Ignore US Copyrights

The back and forth battle between the US and Antigua is long and involved. You can read the background if you want, but the short version is that the US suddenly claimed that Antigua-based online gambling sites were in violation of US anti-gambling laws. Antigua took offense at this, and noted that it appeared to violate free trade agreements between the two countries, most specifically because the US still allowed certainly types of domestic online gambling. The issue went to the WTO multiple times, and every time Antigua won -- and every time the US ignored the decision. At one point, the US pretended it won the ruling, and another time it announced that it was simply, unilaterally, changing its trade agreement with Antigua.

VocalTec Communications To Sell Patents For $12.5 Million

May 28, 2008 (FinancialWire) VocalTec Communications Ltd. (NASDAQ: VOCL) (Current Market Cap. US$3.84 Mil.) has signed a patent purchase agreement to sell selected patents to Karo Millennium J.P. L.L.C. Other companies trading in VocalTec s industry include AT&T Inc. (NYSE: T), Verizon Communications Inc. (NYSE: VZ), an BCE Inc. (NYSE: BCE). Pursuant to the PPA, VocalTec will sell 11 patents and certain patent-related rights, out of the company s current portfolio of 22 patents, for the aggregate selling price of $12.5 million. The patents to be sold consist of nine US patents, one Israel patent, and one Australian patent. Consummation of the transaction is subject to certain conditions, including approval of the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor.

Novosom Granted US and European Patents for RNAi-Delivering Smarticles(R)

Company will be presenting at BioEquity in Amsterdam and BIO2008 in San Diego HALLE, Germany--(Business Wire)-- Novosom AG today announced that it has been granted patents for both the USA and Europe for its Drug Delivery technology Smarticles(R). Smarticles(R) are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells. At the same time Novosom announced that it has been selected to present at both BioEquity (May 28-29, 2008, Hotel Okura, Amsterdam, the Netherlands) and the 2008 BIO Business Forum which takes place during BIO2008 (June 17-20, 2008, San Diego Convention Center, California, USA). The US patent is entitled "Amphoteric liposomes and their use" and the US patent number is US 7371404.

European software patents via treaty?

PRESS RELEASE -- [ Europe / Economy / Innovation ] ======================================================================== McCreevy wants to legalise Software Patents via a US-EU patent treaty ======================================================================== Brussels, 13 May 2008 -- European Commissioner McCreevy is pushing for a bilateral patent treaty with the United States. This Tuesday 13 May in Brussels, White House and European representatives will try to adopt a tight roadmap for the signature of a EU-US patent treaty by the end of the year. Parts of the proposed treaty will contain provision on software patents, and could legalise them on both sides of the Atlantic. "TEC talks are the current push for software patents. The US want to eliminate the higher standards of the European Patent Convention.

Kabira Announces Its Java Technology at JavaOne

Kabira Technologies announced that it is building a Java technology-enabled product to work with its core product technology, the Kabira eXtreme Transaction Platform (KXTP) software. Marrying a Java technology development environment to the Kabira Runtime enables an application developer to inherit integrated transactionality, high performance, transparent distribution, persistent shared memory data, high availability and high-speed channels from Kabira's technology into native Java applications, while preserving the robustness of the Kabira runtime technology.

Kabira Announces Its Java Technology at JavaOne

Kabira Technologies announced that it is building a Java technology-enabled product to work with its core product technology, the Kabira eXtreme Transaction Platform (KXTP) software. Marrying a Java technology development environment to the Kabira Runtime enables an application developer to inherit integrated transactionality, high performance, transparent distribution, persistent shared memory data, high availability and high-speed channels from Kabira's technology into native Java applications, while preserving the robustness of the Kabira runtime technology.

Hybris Announces its Presence in US Market at Internet Retailer 2008

A Strategic Partnership With Arvato Systems and the Win of Major US Customers Signal the Entry of Multi-Channel e-Commerce Vendor Hybris Into the US Market CHICAGO (CNW) - Hybris, http://www.hybris.com, a leading multi-channel communication and commerce software vendor, today announced its entry into the US market by exhibiting at the Internet Retailer 2008 event in Chicago (IRCE 08) where it will be exhibiting with Arvato Systems at booth number 711. This follows a US partnership agreement made between Hybris and Arvato Systems and the company gaining its first US-only customer wins.

Luminus Devices Collects Ten More Patents

Luminus Devices, Inc., the developer and manufacturer of PhlatLight(R) (Photonic Lattice) LEDs that are used in display and lighting applications, today announced it has received its 21st United States patent for its PhlatLight technology. This rapidly growing patent portfolio highlights Luminus Devices' technology leadership in the LED industry. And with 120 additional patents pending in the United States and foreign countries, Luminus will continue its leadership in solid state lighting innovation.

Luminus Devices Collects Ten More Patents

BILLERICA, Mass. (Business Wire) -- Luminus Devices, Inc., the developer and manufacturer of PhlatLight(R) (Photonic Lattice) LEDs that are used in display and lighting applications, today announced it has received its 21st United States patent for its PhlatLight technology. This rapidly growing patent portfolio highlights Luminus Devices' technology leadership in the LED industry. And with 120 additional patents pending in the United States and foreign countries, Luminus will continue its leadership in solid state lighting innovation.

Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane

BERKELEY HEIGHTS, N.J., June 10, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated announced that the Company has received notice of allowances for two major patents from the European Patent Office for its pipeline product, tesetaxel, a leading oral taxane. The patents relate to composition of matter for the tesetaxel drug substance and to processes for its synthesis. The Company plans to broadly secure validation of these patents throughout the major countries in Europe. The European patents complement existing patents that have already issued in the United States. Genta holds worldwide exclusive licenses to these patents.

Kabira(R) Announces Creation of a Java(TM) Technology-Enabled Product to Complement Its Kabira eXtreme Transaction Platform(TM) Software (KXTP)

SAN FRANCISCO, CA -- 05/06/08 -- Kabira Technologies Inc., a leader in extreme transaction processing software for global enterprises, announced today at the 2008 JavaOne(TM) Conference in San Francisco, California that it is building a Java technology-enabled product to work with its core product technology, the Kabira eXtreme Transaction Platform (KXTP) software. Marrying a Java technology development environment to the Kabira Runtime enables an application developer to inherit integrated transactionality, high performance, transparent distribution, persistent shared memory data, high availability and high-speed channels from Kabira's technology into native Java applications, while preserving the robustness of the Kabira runtime technology.

Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications...

Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd. NEW YORK, May 19 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has entered into a license agreement with Wyeth (NYSE: WYE) and Elan Pharma International Ltd. ("Elan") regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease. Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered b

Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.

NEW YORK, May 19, 2008 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has entered into a license agreement with Wyeth and Elan Pharma International Ltd. ("Elan") regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease. Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered by patents that issue from Intellect's patent applications.

International Companies Require China-Specific Patent Strategies

Shanghai, China – May 22, 2008: China, one of the world’s largest and most promising markets, has seen a 20 percent annual increase in patent application filings over the last fifteen years. In 2007, the State Intellectual Property Office (SIPO) of China received 694,153 patent applications, an increase of 21.1 percent over the previous year. These applications included filings for all three types of patents granted in China: Invention patents (valid for 20 years from the date of filing), Utility Models (valid for 10 years), and Design patents (also valid for 10 years). With regard to invention patents (20 year patents), China is currently third in the world behind the United States and Japan. In its latest study, Evalueserve, a global research and analytics firm, forecasts that if patent filings in China continue to grow at the current r

Integrate Legacy Web Applications as Full Page IFrames in WebLogic Portal

One of the many web site headaches that portal technology was expected to cure is the need for IFrames to integrate content and functionality between web applications. Portals provide a quick, clean approach to combine multiple applications into a single user interface. Intranets rapidly adopted the portal approach to combine the multitude of employee content and self-service applications into a single starting place with great success. The employee portal had two huge advantages over the earlier collection of internal sites, vendor sites, and emails: The employee only needed one URL to find what they needed, and they used it.

Search took 0.75 seconds.